CNST News and Press, Constellation Pharmaceuticals Inc. From 06/02/21

Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ...

Gainers: BriaCell Therapeutics (BCTX) +91%.AMC Entertainment (AMC) +76%.Constellation Pharmaceuticals (CNST) +67%.Bed Bath & Beyond (BBBY) +45%.PetMed Express (PETS) +34%.Urban One (UONE) +31%.Vision Marine Technologies (VMAR) +28%.U.S. Well Services (USWS) +24%.Skillz (SKLZ)&#x...

Shares of Constellation Pharmaceuticals (NASDAQ: CNST) had skyrocketed 66.7% as of 12:01 p.m. EDT on Wednesday. The huge gain came after MorphoSys (NASDAQ: MOR) announced that it will acquire Constellation for $1.7 billion. MorphoSys was attracted to Constellation for it...

Do You Have These Top Health Care Stocks On Your June 2021 Watchlist? Given the current state of the stock market now, investors may be turning their attention towards health care stocks. For the most part, this could be because of inflation fears quelling the current momentum i...

Gainers: BriaCell Therapeutics BCTX +151%, Constellation Pharmaceuticals CNST +67%, Soleno Therapeutics SLNO +46%, Stealth BioTherapeutics (MITO) +24%, Aerpio Pharmaceuticals (ARPO) +9%.Losers: iRhythm Technologies IRTC -18%, Progenity (P...

BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...

Constellation Pharmaceuticals (CNST) has climbed ~61.3% in the pre-market after announcing an agreement with MorphoSys AG (MPSYF) whereby MorphoSys will acquire Constellation for $34.00 per share in cash for a total equity value of ~$1.7B.Per the terms of the agreement, which i...

Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation Pharmaceuticals Investment is anchored by royalties on Janssen’s Tremfya Partnership also includes royalties on four development-stage therapies, Developme...

Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability ...

CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an ...